Zhu Ying, Bian Jingfang, Lu Daqian, Wang Qiong, Gong Boteng, Li King-Kit, Yu Fengjuan, Cheung Jimmy Ka-Wai, Ji Xiaowen, Zhang Hongmei, Du Bei, Nian Hong, To Chi-Ho, Wei Ruihua, Lam Thomas Chuen
Tianjin International Joint Research and Development Centre of Ophthalmology and Vision Science, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.
Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Data Brief. 2020 Nov 17;33:106526. doi: 10.1016/j.dib.2020.106526. eCollection 2020 Dec.
Atropine, a non-selective muscarinic antagonist, is known to slow down myopia progression in human adolescents and in several animal models. However, its underlying molecular mechanism is unclear. The present work built a monocular form-deprivation myopia (FDM) guinea pig model, using facemasks as well as atropine treatment on FDM eyes for 2 and 4 weeks. Retinal protein changes in response to the FDM and effects of topical administration of atropine were screened for the two periods using fractionated isobaric tags for a relative and absolute quantification (iTRAQ) approach coupled with nano-liquid chromatography-tandem mass spectrometry (nano-LC-MS/MS) (=24, 48 eyes). Retinal tissues from another cohort receiving 4-weeks FDM with atropine treatment (=12, 24 eyes) with more significant changes were subjected to sequential window acquisition of all theoretical mass spectra (SWATH-MS) proteomics for further protein target confirmation. A total of 1695 proteins (8875 peptides) and 5961 proteins (51871 peptides) were identified using iTRAQ and SWATH approaches, respectively. Using the Paragon algorithm in the ProteinPilot software, the three most significantly up-regulated and down-regulated proteins that were commonly found in both ITRAQ and SWATH experiments are presented. All raw data generated from the work were submitted and published in the Peptide Atlas public repository (http://www.peptideatlas.org/) for general release (Data ID PASS01507).
阿托品是一种非选择性毒蕈碱拮抗剂，已知其可减缓人类青少年和多种动物模型中的近视进展。然而，其潜在的分子机制尚不清楚。本研究建立了一种单眼形觉剥夺性近视（FDM）豚鼠模型，使用面罩对FDM眼进行阿托品治疗2周和4周。使用相对和绝对定量的等压标记物分级分离（iTRAQ）方法结合纳升液相色谱-串联质谱（nano-LC-MS/MS）（每组n = 24只动物，48只眼），筛选这两个时期视网膜蛋白对FDM的反应以及局部应用阿托品的效果。对另一组接受4周FDM并进行阿托品治疗（n = 12只动物，24只眼）且变化更显著的视网膜组织进行全理论质谱的顺序窗口采集（SWATH-MS）蛋白质组学分析，以进一步确认蛋白质靶点。分别使用iTRAQ和SWATH方法鉴定出总共1695种蛋白质（8875个肽段）和5961种蛋白质（51871个肽段）。使用ProteinPilot软件中的Paragon算法，展示了在iTRAQ和SWATH实验中均普遍存在的三种上调和下调最显著的蛋白质。本研究产生的所有原始数据已提交并发表在肽图谱公共数据库（http://www.peptideatlas.org/）中以供公开发布（数据ID PASS01507）。
